Xinqi Li , Yueze Liu , Feihan Zhou , Wenbo Guo , Guangyu Chen , Jinxin Tao , Jingmin Huang , Jiangdong Qiu , Hao Chen , Bo Ren , Lei You , Yanan Shi , Gang Yang , Taiping Zhang , Jin Gu , Yupei Zhao
{"title":"通过跨时间上下文图模型解读胰腺导管腺癌对化疗的单细胞水平反应。","authors":"Xinqi Li , Yueze Liu , Feihan Zhou , Wenbo Guo , Guangyu Chen , Jinxin Tao , Jingmin Huang , Jiangdong Qiu , Hao Chen , Bo Ren , Lei You , Yanan Shi , Gang Yang , Taiping Zhang , Jin Gu , Yupei Zhao","doi":"10.1016/j.canlet.2025.217751","DOIUrl":null,"url":null,"abstract":"<div><div>Gemcitabine is commonly used for pancreatic ductal adenocarcinoma (PDAC), one of the most lethal cancer types. However, the drug resistance is a critical challenge for improving the PDAC chemotherapy. Here, we applied single-cell RNA sequencing (scRNA-seq) on PDAC patient-derived xenograft (PDX) models to study the complex cellular responses related to the gemcitabine resistances. To reconstruct dynamic tumor cell responses from these static scRNA-seq snapshots, we proposed scConGraph, a scalable bi-layer graph model that can efficiently integrate cross-time context information. Based on scConGraph, we observed that stemness and endoplasmic reticulum stress contribute to intrinsic resistance. As for acquired resistance, cancer cells may resist or evade gemcitabine treatment by activating the cell cycle, entering quiescence, or inducing epithelial-mesenchymal transition. Notably, <em>GDF15</em> exhibited recurrent and significant upregulations among acquired-resistance cell subpopulations. Experimental validation confirmed that inhibiting <em>GDF15</em> sensitizes tumor cells to gemcitabine, suggesting a potential target for gemcitabine-induced chemoresistance.</div></div>","PeriodicalId":9506,"journal":{"name":"Cancer letters","volume":"626 ","pages":"Article 217751"},"PeriodicalIF":9.1000,"publicationDate":"2025-04-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Decipher the single-cell level responses to chemotherapy in pancreatic ductal adenocarcinoma by a cross-time context graph model\",\"authors\":\"Xinqi Li , Yueze Liu , Feihan Zhou , Wenbo Guo , Guangyu Chen , Jinxin Tao , Jingmin Huang , Jiangdong Qiu , Hao Chen , Bo Ren , Lei You , Yanan Shi , Gang Yang , Taiping Zhang , Jin Gu , Yupei Zhao\",\"doi\":\"10.1016/j.canlet.2025.217751\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>Gemcitabine is commonly used for pancreatic ductal adenocarcinoma (PDAC), one of the most lethal cancer types. However, the drug resistance is a critical challenge for improving the PDAC chemotherapy. Here, we applied single-cell RNA sequencing (scRNA-seq) on PDAC patient-derived xenograft (PDX) models to study the complex cellular responses related to the gemcitabine resistances. To reconstruct dynamic tumor cell responses from these static scRNA-seq snapshots, we proposed scConGraph, a scalable bi-layer graph model that can efficiently integrate cross-time context information. Based on scConGraph, we observed that stemness and endoplasmic reticulum stress contribute to intrinsic resistance. As for acquired resistance, cancer cells may resist or evade gemcitabine treatment by activating the cell cycle, entering quiescence, or inducing epithelial-mesenchymal transition. Notably, <em>GDF15</em> exhibited recurrent and significant upregulations among acquired-resistance cell subpopulations. Experimental validation confirmed that inhibiting <em>GDF15</em> sensitizes tumor cells to gemcitabine, suggesting a potential target for gemcitabine-induced chemoresistance.</div></div>\",\"PeriodicalId\":9506,\"journal\":{\"name\":\"Cancer letters\",\"volume\":\"626 \",\"pages\":\"Article 217751\"},\"PeriodicalIF\":9.1000,\"publicationDate\":\"2025-04-26\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cancer letters\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0304383525003179\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer letters","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0304383525003179","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
Decipher the single-cell level responses to chemotherapy in pancreatic ductal adenocarcinoma by a cross-time context graph model
Gemcitabine is commonly used for pancreatic ductal adenocarcinoma (PDAC), one of the most lethal cancer types. However, the drug resistance is a critical challenge for improving the PDAC chemotherapy. Here, we applied single-cell RNA sequencing (scRNA-seq) on PDAC patient-derived xenograft (PDX) models to study the complex cellular responses related to the gemcitabine resistances. To reconstruct dynamic tumor cell responses from these static scRNA-seq snapshots, we proposed scConGraph, a scalable bi-layer graph model that can efficiently integrate cross-time context information. Based on scConGraph, we observed that stemness and endoplasmic reticulum stress contribute to intrinsic resistance. As for acquired resistance, cancer cells may resist or evade gemcitabine treatment by activating the cell cycle, entering quiescence, or inducing epithelial-mesenchymal transition. Notably, GDF15 exhibited recurrent and significant upregulations among acquired-resistance cell subpopulations. Experimental validation confirmed that inhibiting GDF15 sensitizes tumor cells to gemcitabine, suggesting a potential target for gemcitabine-induced chemoresistance.
期刊介绍:
Cancer Letters is a reputable international journal that serves as a platform for significant and original contributions in cancer research. The journal welcomes both full-length articles and Mini Reviews in the wide-ranging field of basic and translational oncology. Furthermore, it frequently presents Special Issues that shed light on current and topical areas in cancer research.
Cancer Letters is highly interested in various fundamental aspects that can cater to a diverse readership. These areas include the molecular genetics and cell biology of cancer, radiation biology, molecular pathology, hormones and cancer, viral oncology, metastasis, and chemoprevention. The journal actively focuses on experimental therapeutics, particularly the advancement of targeted therapies for personalized cancer medicine, such as metronomic chemotherapy.
By publishing groundbreaking research and promoting advancements in cancer treatments, Cancer Letters aims to actively contribute to the fight against cancer and the improvement of patient outcomes.